Ardelyx, Inc.

XNASHealth care

Last traded price · USD

$3.29

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:59 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $3.29
Volume: 241
Day's high: —
Day's low: —

In brief

Ardelyx, Inc. is a health care company listed on Nasdaq, valued at about $849M.
Its shares closed at $3.29 on 4 Nov 2026, down 41.3% over the past year.
From India you can buy ARDX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Ardelyx, Inc. (ARDX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ARDX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ARDX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −0.6% (SPY −1.6%, XLV +13.5%). 3 months: −33.0% (SPY −0.4%, XLV +15.5%). 1 year: −41.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ARDX, SPY and XLV · as of 4 Nov 2026
11.3% above its 52-week low
Closed at $3.29 on 4 Nov 2026: 60.8% below the 52-week high of $8.40 (23 Jan 2026) and 11.3% above the low of $2.96 (28 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
6.5 days to cover short interest
30.2M shares were sold short at the 15 Oct 2026 settlement, 12.1% of the 249.2M shares outstanding; covering them would take 6.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $3.29 was 2.8% below its 50-day average ($3.39) and 37.6% below its 200-day average ($5.27). It has closed below the 200-day for 93 sessions, since 25 Jun 2026. The 50-day average crossed below the 200-day on 30 Jun 2026, 89 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 10.9M shares was 2.5× the average of the 30 sessions before it (4.4M), as the price rose 8.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.6%

6 months−53.7%

1 year−41.3%

5 years+165.3%

Newswire

About

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Website

Notable moves

January 8, 2024
+32.79%
November 17, 2022
+40.98%
December 2, 2021
+38.21%

Newswire

About

Website

Notable moves

January 8, 2024
+32.79%
November 17, 2022
+40.98%
December 2, 2021
+38.21%

Ardelyx, Inc.

XNASHealth care

Last traded price · USD

$3.29

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:59 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $3.29
Volume: 241
Day's high: —
Day's low: —

In brief

Ardelyx, Inc. is a health care company listed on Nasdaq, valued at about $849M.
Its shares closed at $3.29 on 4 Nov 2026, down 41.3% over the past year.
From India you can buy ARDX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Ardelyx, Inc. (ARDX) shares from India?

Do I need the price of a whole ARDX share to invest?

How much can I invest in US stocks in a year?

Can I trade ARDX options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −0.6% (SPY −1.6%, XLV +13.5%). 3 months: −33.0% (SPY −0.4%, XLV +15.5%). 1 year: −41.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ARDX, SPY and XLV · as of 4 Nov 2026
11.3% above its 52-week low
Closed at $3.29 on 4 Nov 2026: 60.8% below the 52-week high of $8.40 (23 Jan 2026) and 11.3% above the low of $2.96 (28 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
6.5 days to cover short interest
30.2M shares were sold short at the 15 Oct 2026 settlement, 12.1% of the 249.2M shares outstanding; covering them would take 6.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $3.29 was 2.8% below its 50-day average ($3.39) and 37.6% below its 200-day average ($5.27). It has closed below the 200-day for 93 sessions, since 25 Jun 2026. The 50-day average crossed below the 200-day on 30 Jun 2026, 89 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 10.9M shares was 2.5× the average of the 30 sessions before it (4.4M), as the price rose 8.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.6%

6 months−53.7%

1 year−41.3%

5 years+165.3%

Newswire

About

Website

Notable moves

January 8, 2024
+32.79%
November 17, 2022
+40.98%
December 2, 2021
+38.21%

Newswire

About

Website

Notable moves

January 8, 2024
+32.79%
November 17, 2022
+40.98%
December 2, 2021
+38.21%

Ardelyx, Inc.

Ardelyx, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.3% above its 52-week low

6.5 days to cover short interest

Below its 50- and 200-day averages

Volume 2.5× its 30-session average on 4 Nov 2026

Ardelyx, Inc.

Ardelyx, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.3% above its 52-week low

6.5 days to cover short interest

Below its 50- and 200-day averages

Volume 2.5× its 30-session average on 4 Nov 2026